Adam K. Simpson - 20 Dec 2023 Form 4 Insider Report for Icosavax, Inc.

Role
Chief Executive Officer, Director
Signature
/s/ Elizabeth Bekiroglu, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
20 Dec 2023
Net transactions value
-$2,125,704
Form type
4
Filing time
22 Dec 2023, 18:27:38 UTC
Previous filing
01 Aug 2023
Next filing
04 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ICVX Common Stock Sale $961,509 -62,205 -25% $15.46 184,724 20 Dec 2023 Direct F1, F2
transaction ICVX Common Stock Options Exercise $106,677 +102,574 +56% $1.04* 287,298 21 Dec 2023 Direct
transaction ICVX Common Stock Options Exercise $98,800 +40,000 +14% $2.47* 327,298 21 Dec 2023 Direct
transaction ICVX Common Stock Options Exercise $19,608 +23,343 +7.1% $0.8400* 350,641 21 Dec 2023 Direct
transaction ICVX Common Stock Sale $772,220 -50,000 -14% $15.44 300,641 21 Dec 2023 Direct F3, F4
transaction ICVX Common Stock Sale $617,060 -40,000 -13% $15.43 260,641 21 Dec 2023 Direct F5
holding ICVX Common Stock 531,576 20 Dec 2023 By family trust
holding ICVX Common Stock 129,032 20 Dec 2023 By family trust
holding ICVX Common Stock 129,032 20 Dec 2023 By family trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ICVX Stock Option (Right to Buy) Options Exercise $0 -102,574 -25% $0.000000 314,676 21 Dec 2023 Common Stock 102,574 $1.04 Direct F6
transaction ICVX Stock Option (Right to Buy) Options Exercise $0 -40,000 -14% $0.000000 237,146 21 Dec 2023 Common Stock 40,000 $2.47 Direct F7
transaction ICVX Stock Option (Right to Buy) Options Exercise $0 -23,343 -83% $0.000000 4,789 21 Dec 2023 Common Stock 23,343 $0.8400 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Reflects shares sold to cover withholding taxes upon accelerated vesting of restricted stock unit awards pursuant to a Rule10b5-1 instruction letter dated December 6, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.41 to $15.50. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The sales were effected pursuant to a Rule 10b5-1 instruction letter dated December 6, 2021.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.39 to $15.60. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.40 to $15.495. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 25% of the shares subject to the option vested on January 14, 2022, and 1/48th of the shares subject to the option vest monthly thereafter.
F7 One-third (1/3rd) of the shares subject to the option shall vest on each of the first three anniversaries of November 10, 2022, subject to the reporting person's continued service through the applicable vesting date.
F8 25% of the shares subject to the option vested on February 21, 2021, and 1/48th of the shares subject to the option vest monthly thereafter.